Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Tenofovir disoproxil fumarate 300 mg only, not tenofovir alafenamide or a fixed-dose combination.
The NIH addition is specifically tenofovir disoproxil fumarate (TDF). Do not apply it to tenofovir alafenamide (TAF) or a fixed-dose combination.
Check source scope before reading a dose
NIH adult ARV table - tenofovir disoproxil fumarate
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl mL/min; single-agent TDF only
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional
NIH adult ARV table - tenofovir disoproxil fumarate
NIH ClinicalInfo adult ARV panel · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl mL/min; single-agent TDF only Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Single-agent TDF: usual 300 mg orally daily. CrCl 30-49: 300 mg every 48 hours; 10-29: 300 mg every 72-96 hours; <10 without HD: no recommendation. HD: 300 mg every 7 days after dialysis. Do not apply this to TAF or fixed combinations.
RDM30-099-tenofovir-1 · Source locator: NIH adult ARV table - tenofovir disoproxil fumarate; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.